RecruitingPhase 2NCT07255963

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

A Prospective Study of Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Sponsor

The First Affiliated Hospital of Soochow University

Enrollment

29 participants

Start Date

Nov 30, 2025

Study Type

INTERVENTIONAL

Conditions

DLBCL - Diffuse Large B Cell Lymphoma

Summary

This study aims to evaluate the efficacy of combining pirtobrutinib, lisaftoclax, and rituximab (PVR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy and to explore a more effective treatment strategy for this patient population.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a three-drug combination — pirtobrutinib, lisaftoclax, and rituximab — in patients with diffuse large B-cell lymphoma (DLBCL, an aggressive blood cancer) that has come back or stopped responding to previous treatments. **You may be eligible if...** - You are 18 or older - You have confirmed DLBCL that has relapsed or is not responding to treatment - You have at least one measurable tumor site - You have a life expectancy of at least 3 months and a reasonable performance status **You may NOT be eligible if...** - Your cancer has spread to the brain or spinal fluid - You have had certain prior treatments that overlap with the study drugs - You have significant liver, kidney, or heart problems - You have active serious infections Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.